{"id":"W4379283505","doi":"10.1200/jco.2023.41.16_suppl.tps2673","title":"A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Queen's University; McMaster University; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; Juravinski Cancer Centre","funders":"AstraZeneca Canada","keywords":"Durvalumab; Medicine; Tolerability; Discontinuation; Adverse effect; Internal medicine; Oncology; Tremelimumab; Prednisone; Leukocytopenia; Toxicity; Cancer; Surgery; Nivolumab; Immunotherapy; Ipilimumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001293744,0.001437399,0.002032717,0.0003458952,0.0004755326,0.0008702372,0.0008605451,0.001149593,0.005349862],"category_scores_gemma":[0.0009442159,0.0005317602,0.001592288,0.0003835606,0.0007594668,0.0006154062,0.0002812556,0.003213475,0.001126488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001152482,"about_ca_system_score_gemma":0.002123499,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002910297,"about_ca_topic_score_gemma":0.00646311,"domain_scores_codex":[0.9995969,0.0001526037,0.00002043019,0.00007188408,0.00004093344,0.000117325],"domain_scores_gemma":[0.9992332,0.0001272238,0.0001184501,0.00005865477,0.00004272483,0.0004197502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7816728,0.08302917,0.007446268,0.001067116,0.001519272,0.0006330474,0.0002878336,0.001205665,0.01949979,0.0002424378,0.005461656,0.09793497],"study_design_scores_gemma":[0.6487479,0.3372683,0.009246084,0.00003593864,0.000404631,0.0003887482,0.00004657592,0.0004242691,0.0009377243,0.0001033889,0.002379192,0.00001725771],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9875439,0.003332529,0.0004384126,0.0005145667,0.0002167149,0.003553983,0.00171212,0.0001035174,0.002584166],"genre_scores_gemma":[0.9869429,0.002321179,0.001227888,0.001074007,0.0002425695,0.002712265,0.002861038,0.00002624507,0.002591876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005349862,"threshold_uncertainty_score":0.01789713,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1008641121674163,"score_gpt":0.4639526084612532,"score_spread":0.3630884962938369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}